Send to

Choose Destination
See comment in PubMed Commons below
Ophthalmology. 2016 Apr;123(4):817-28. doi: 10.1016/j.ophtha.2015.12.009. Epub 2016 Jan 16.

The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.

Collaborators (141)

Scholl HP, Strauss RW, Wolfson Y, Bittencourt M, Shah SM, Ahmed M, Schonbach E, Traboulsi E, Ehlers J, Marino M, Crowe S, Briggs R, Borer A, Pinter A, Fecko T, Brugnoni N, Sunness JS, Applegate C, Russell L, Michaelides M, Moore A, Webster A, Connor S, McCudden V, Pefkianaki M, Aboshiha J, Liew G, Fujinami K, Holder G, Robson A, King A, Cajas Narvaez DI, Barnard K, Grigg C, Dunbar H, Obadeyi Y, Girard-Claudon K, Swann H, Rughani A, Amoah C, Carrington D, Bibi K, Co ET, Carter A, Georgiou A, Lewis S, Shaheen S, Shinmar H, Burton L, Bernstein P, Wegner K, Sawyer BL, Carlstrom B, Farnsworth K, Fry C, Chandler M, Jenkins G, Creel D, Birch D, Wang YZ, Rodriguez L, Locke K, Klein M, Mejia P, Cideciyan AV, Jacobson SG, Schwartz SB, Matsui R, Gruzensky M, Roman AJ, Zrenner E, Nasser F, Hahn GA, Wilhelm B, Peters T, Beier B, Koenig T, Kramer S, Sahel JA, Mohand-Said S, Audo I, Laurent-Coriat C, Sliesoraityte I, Zeitz C, Boyard F, Tran MH, Chapon M, Chaumette C, Amaudruz J, Ganem V, Sancho S, Girmens A, Scholl HP, Strauss RW, Wolfson Y, Shah SM, Ahmed M, Schonbach E, Wojciechowski R, Khan S, Emmert DG, Cain D, Herring M, Bassinger J, Liberto L, West S, Ervin AM, Munoz B, Kong X, Dreger K, Jones J, Bomotti S, Sadda S, Jha A, Ho A, Kramer B, Hariri A, Blanquel GR, Lam N, Pitetta S, Shi Y, Tawdros R, Petrossian C, Jenkins D, Gupta M, Zhou YD, Aguilar K, Chan C, Santos L, Seo B, Sison C, Perez S, Chao S, Miyasato K, Higgins J, Luna Z, Menchaca A, Gonzalez N, Robledo V, Carig K, Baker K.

Author information

Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland; Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, University College London, London, United Kingdom; Department of Ophthalmology, Medical University Graz, Graz, and Department of Ophthalmology, Johannes Kepler University Linz, Linz, Austria.
Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California.
Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Sorbonne Universités, University Pierre et Marie Curie (UPMC) Université de Paris 06, Institut national de la santé et de la recherche médicale (INSERM), Centre national de la recherche scientifique (CNRS), Institut de la Vision, Centre Hospitalier National d'Ophtalmologie (CHNO) des Quinze-Vingts, Paris, France.
Hoover Low Vision Rehabilitation Services, Greater Baltimore Medical Center, Baltimore, Maryland.
Retina Foundation of the Southwest, Dallas, Texas.
Moran Eye Center, University of Utah School of Medicine, Salt Lake City, Utah.
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, University College London, London, United Kingdom.
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Center for Ophthalmology, Eberhard-Karls University Hospital, Tuebingen, Germany.
Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland; Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Electronic address:



To describe the design and baseline characteristics of patients enrolled into 2 natural history studies of Stargardt disease (STGD1).


Multicenter retrospective and prospective cohort studies.


Three hundred sixty-five unique patients aged 6 years and older at baseline harboring disease-causing variants in the ABCA4 gene and with specified ocular lesions were enrolled from 9 centers in the United States and Europe.


In the retrospective study, patients contributed medical record data from at least 2 and up to 4 visits for at least 1 examination modality: fundus autofluorescence (FAF), spectral-domain (SD) optical coherence tomography (SD OCT), and/or microperimetry (MP). The total observational period was at least 2 years and up to 5 years between single visits. Demographic and visual acuity (VA) data also were obtained. In the prospective study, eligible patients were examined at baseline using a standard protocol, with 6-month follow-up visits planned for a 2-year period for serial Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected VA, SD OCT, FAF, and MP.


Design and rationale of a multicenter study to determine the progression of STGD1 in 2 large retrospective and prospective international cohorts. Detailed baseline characteristics of both cohorts are presented, including demographics, and structural and functional retinal metrics.


Into the retrospective study, 251 patients (458 eyes) were enrolled; mean follow-up ± standard deviation was 3.9±1.6 years. At baseline, 36% had no or mild VA loss, and 47% of the study eyes had areas of definitely decreased autofluorescence (DDAF) with an average lesion area of 2.5±2.9 mm(2) (range, 0.02-16.03 mm(2)). Two hundred fifty-nine patients (489 eyes) were enrolled in the prospective study. At baseline, 20% had no or mild VA loss, and 64% had areas of DDAF with an average lesion area of 4.0±4.4 mm(2) (range, 0.03-24.24 mm(2)). The mean retinal sensitivity with MP was 10.8±5.0 dB.


The ProgStar cohorts have baseline characteristics that encompass a wide range of disease severity and are expected to provide valuable data on progression based on serial quantitative measurements derived from multiple methods, which will be critical to the design of planned clinical trials.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center